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Abstract Recently, cholecystokinin has been reported to be 
important in regulating the growth of pancreatic cancer. We 
investigated the effect of loxiglumide (LXG), a cholecytskinin 
receptor antagonist, on the invasiveness of two human pancreatic 
cancer cell lines. Cells were treated with LXG for 24 h, and 
examined in the invasion assay. The expression and activity of 
MMP-9 in supernatants from cancer cells were analyzed by 
V~estern blotting and zymogram. Interestingly, the invasiveness 
of cancer cells and expression of MMP-9 were decreased by 
LXG in a dose-dependent manner. LXG may be a useful 
therapeutic agent against pancreatic cancer. 
K,'y words: Cholecystokinin receptor; Gelatinase; Invasion; 
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1. Introduction 
Although many therapeutic agents have been tried in pan- 
creatic cancer, its prognosis remains poor. Invasive diseases 
w th liver metastasis, vascular or retroperitoneal invasions are 
already present in many patients with pancreatic ancer at the 
time of diagnosis. In tumour invasion and cancer cell meta- 
stasis, matrix metalloproteinases (MMPs) play important 
n',les in the degradation of the basement membrane and ex- 
tracellular matrix (ECM). The expression of MMP-9, whose 
st bstrate is gelatin, has been reported in several human carci- 
n~mas such as lung [1], breast [2] and several metastatic tu- 
mour models [3,4]. These observations uggest hat MMP-9 
may play an important role in tumour cell invasion [5-7]. 
Cholecystokinin (CCK) is a gut hormone that stimulates 
pancreatic enzyme secretion [8], and gallbladder contraction 
[9]. Recent studies have reported that CCK promotes pan- 
c~ eatic carcinogenesis n animals [10-12], and also stimulates 
t te  growth of two human pancreatic ancer cell lines (PANC- 
1 and MIA  PaCa-2) via a low-affinity CCK receptor [13]. 
Loxiglumide (LXG) has been reported as a selective and spe- 
cific peripheral CCK-A receptor antagonist [14]. In Japan, a 
clinical trial has reported that LXG may be a useful agent for 
pmcreatit is [15]. A recent study has reported that LXG in- 
h bits the growth of human pancreatic ancer cell lines [16]. 
tiowever, no known study has reported the relationship be- 
tween CCK receptors and the invasiveness of human pan- 
c~eatic ancer cells. 
*Corresponding author. Fax: (81) (82) 257-5194. 
Abbreviations: CCK, cholecystokinin; DMEM, Dulbecco's modified 
Eagle's medium; ECM, extracellular matrix; FBS, foetal bovine 
scrum; LXG, loxiglumide; MMP, matrix metalloproteinase. 
The present study is the first to show that the CCK receptor 
antagonist, LXG, inhibits the invasiveness of human pan- 
creatic cancer cell lines. 
2. Materials and methods 
2.1. Cell culture 
Two human pancreatic cancer cell lines, PANC-1 and MIA PaCa-2, 
purchased from the American Type Culture Collection, were main- 
tained in Dulbecco's modified Eagle's medium (DMEM) (Gibco Lab., 
Grand Island, NY, USA), pH 7.4, containing 100 U/ml penicillin- 
streptomycin (Sigma Chemical Co., St. Louis, MO, USA) and 10% 
foetal bovine serum (FBS) (Gibco). The cells were grown in 25 cm 2 
plastic flasks (Corning, NY, USA), and placed in 5% CO2 at 37°C. 
2.2. Cell treatment 
LXG was kindly supplied by Kaken Pharmaceutical Co. Ltd., Chi- 
ba, Japan. It was dissolved with phosphate-buffered saline (PBS, Gib- 
co, Grand Island, NY, USA), pH 8.0. CCK-8 (purchased from Pep- 
tide Institute, Inc., Osaka, Japan) was also dissolved with PBS. The 
solution of LXG (1, 5, 10 and 50 p_M) and CCK-8 (10 -9 and 10 -8 M) 
were diluted in PBS just before examination. For in vitro experiments, 
1 × 106 cells/flask were maintained in DMEM supplemented with 0.1% 
FBS. After washing twice with fresh serum-free medium, LXG or 
CCK-8 solutions were added in flasks and maintained in 5% CO2 at 
37°C for 24 h. Thereafter, each supernatant was harvested and cen- 
trifuged at 1500 rpm for 5 min to remove cell debris. The protein 
content of each supernatant was prepared at 25 p-g/ml, and used as 
a sample. Each sample was analyzed by Western blotting and gelatin 
zymogram. 
2.3. Invasion assay 
Cells were harvested followed by exposure to trypsin (0.25%) at 
37°C for 20 min. After centrifugation (1500 rpm for 5 min), cells 
were resuspended in medium, and then examined using a Boyden 
chamber. Cell viability was evaluated with the 0.1% trypan blue ex- 
clusion method. Transwell cell culture chambers (Costar no. 3403, 
Cambridge, MA, USA) with 12-mm diameter filters were used for 
this assay. Polyvinylpyrollidone-free polycarbonate filters (pore size 
12 p-m) were coated with basement membrane matrigel (200 Ixg/filter) 
(Collaborative Research Inc., Bedford, MA, USA). The coated filters 
were placed on Boyden chambers, and the cells (1 x 105) suspended in
DMEM containing 0.1% FBS were placed in the upper chamber. 
DMEM containing 0.1% FBS was placed in the lower compartment 
of the Boyden chambers. The chambers were incubated in 5% CO2 at 
37°C, and the cell numbers of the lower compartment were counted 
hourly for 6 h [17]. The assays were performed in triplicate. 
2.4. Western blot analysis 
A volume of 15 p-I from each sample as described above was pre- 
pared for electrophoresis on a 10% SDS-polyacrylamide g l. The re- 
solved proteins were transferred to a nitrocellulose membrane with 
20% methanol, 25 mM Tris-HCl, pH 8.3 and 192 mM glycine at 
150 mA and 4°C for 3 h. The membrane blocked with the horse serum 
and incubated with a mouse monoclonal anti-MMP-9 antibody (2 ~tg/ 
ml), (IM10, Oncogene Science Inc., Cambridge, MA, USA). After 
incubating with biotinylated antimouse secondary antibody (Vecta- 
stain ABC kit, Vector Labs, Burlingame, California, USA), and a 
streptavidin-horseradish complex (Vectastain ABC kit), the colour 
was developed using diaminobenzidine-hydrogen peroxide (Vectastain 
DAB kit). 
S,)014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
57DI S00 1 4-5793 (96)00245-  1 
242 
2.5. Gelatin zymogram 
A volume of 15/.tl from the same samples as described above was 
applied to 10% polyacrylamide g l containing 2 mg/ml gelatin. After 
electrophoresis, the gel was washed with washing buffer (50 mM Tris- 
HC1, pH 7.4 and 2.5% Triton X-100) at room temperature for 30 min, 
and then placed in incubation buffer (30 mM Tris-HCl, pH 7,4, 0.2 M 
NaCI, 10 mM CaC12 and 0.02% NAN3) at 37°C overnight. The gel 
was stained with 0.02% Coomassie brilliant blue in 20% methanol and 
10% acetic acid, and destained with 20% methanol and 10% acetic 
acid. Molecular weights of the gelatinolytic bands were estimated 
using molecular weight markers (Daiichi Pure Chemicals, Tokyo, Ja- 
pan). 
2.6. Statistical analysis 
Invasion assays were performed in triplicate, and results were ex- 
pressed as mean plus or minus the standard eviation (mean + SD). 
Statistical analysis was performed using regression analysis. Statistical 
significance was assumed with a P value < 0.01. 
3.  Resu l t s  
3.1. Invasion assay 
This assay can simply evaluate the ability of the cells to 
attach and degrade the matrix [17]. These events are consid- 
ered to be important in the invasion of tumour cells through 
the basement membrane. Benign or normal cells except neu- 
trophils did not penetrate through the basement membrane 
matrigel [17]. Figs. 1A and 2A show the penetrating cell 
numbers treated with LXG at 6 h. The generation time of 
PANC-1 and MIA PaCa-2 cells ranging from 10.5 to 11 h 
did not affect the cell number in the lower compartment 
(data not shown). CCK-8, at a dose of 10 -s M, increased 
the numbers of penetrating cells by 50% in PANC-1 and 
40% in MIA PaCa-2 compared to untreated cells. In con- 
trast, LXG, at a dose of 50 p.M, decreased the number of 
penetrating cells by 83.1% in PANC-1, and 82.9% in MIA  
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Fig. 1. Invasion assay using a Boyden chamber in PANC-1. (A) 
Penetrating cell number treated with CCK-8 at 4 h and (B) statisti- 
cal analysis using regression analysis• The cell numbers penetrating 
the matrigel are significantly increased in a dose-dependent manner 
(regression coefficient = 0.94720, p < 0.01). (C) Penetrating cell 
number treated with LXG at 6 h and (D) statistical analysis using 
regression analysis. The cell numbers penetrating the matrigel are 
significantly decreased in a dose-dependent manner (regression 
coefficient = -0.97434, p < 0.01). 
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Fig. 2. Invasion assay using a Boyden chamber in MIA PaCa-2. 
(A) Penetrating cell number treated with CCK-8 at 4 h and (B) sta- 
tistical analysis using regression analysis. The cell numbers penetrat- 
ing the matrigel are significantly increased in a dose-dependent man- 
ner (regression coefficient = 0.93777, P < 0.01). (C) Penetrating cell 
number treated with LXG at 6 h and (D) statistical analysis using a 
regression analysis. The cell numbers penetrating the matrigel are 
significantly decreased in a dose-dependent manner (regression 
coefficient = -0.92608, P < 0.01). 
PaCa-2 compared to untreated cells, respectively. The results 
of regression analysis in PANC-1 and MIA PaCa-2 treated 
with CCK-8 are shown in Figs. 1B and 2B, and those with 
LXG are displayed in Figs. ID and 2D. The numbers of 
penetrating cells were significantly increased with CCK-8, 
and decreased with LXG in a dose-dependent manner 
(P<O.O1). 
3.2. Western blot analysis 
The results of Western blotting to detect the expression of 
MMP-9 in PANC-1 and MIA  PaCa-2 cells are shown in Fig. 
3A-D. The expression of MMP-9 tended to increase with 
CCK-8, and to decrease with LXG in a dose-dependent man- 
ner in both cells. 
3.3. Gelatin zymogram 
A gelatin zymogram assay was performed on each super- 
natant from PANC-1 and MIA  PaCa-2 to examine the effect 
of CCK-8 and LXG on the gelatinase activity of MMP-9. In 
this assay, clear zones against the blue background indicated 
the presence of gelatinolytic activity. Fig. 4A and B demon- 
strates that the gelatinase activities of MMP-9 in PANC-1 and 
MIA  PaCa-2 tended to increase with CCK-8 in a dose-depen- 
dent manner. In contrast, Fig. 4C and D demonstrate that the 
gelatinase activities of MMP-9 in PANC-1 and MIA PaCa-2 
tended to decrease with LXG in a dose-dependent manner. 
CCK-8 or LXG were added to the media from untreated cells, 
and incubated at 37°C for 24 h. However, no effect on the 
gelatinase activities of MMP-9 was observed in the media 
(data not shown). Additionally, CCK-8 and LXG exert no 
growth effect in PANC-1 and MIA  PaCa-2 for 24 h (data 
not shown). 
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4. Discussion 
It has been reported that cancer cells may overexpress some 
receptors which are activated by specific growth factors, and 
cause the activation of growth signal pathways [18]. Human 
pancreatic ancer cells overexpress epidermal growth factor 
( IGF) ,  tumour necrosis factor (TNF-ct) and the receptors 
fi r EGF  [13,19,20]. Some growth factors, such as EGF,  trans- 
fi rming growth factor-beta nd TNF-e~, are considered to be 
irduced and activated MMP-9 [21,22]. 
A recent study has reported that CCK receptors overex- 
wess in human pancreatic ancer [23]. CCK receptors acti- 
wtted by CCK may stimulate the growth of human pancreatic 
c; ncer cell lines [13]. LXG, a specific CCK receptor antago- 
nst,  has been reported to inhibit DNA synthesis and the 
gowth  of human pancreatic ancer [16]. Many previous re- 
p)rts have provided evidence in support of CCK receptors 
paying as growth factor receptors. However, little is known 
a to whether CCK receptors have any potentials in the inva- 
s~ veness of cancer cells. This is the first study to evaluate the 
r~ lationship between the CCK receptor and the invasiveness 
o "human pancreatic ancer cell lines. Surprisingly, this study 
hts demonstrated that CCK receptors may play a role not 
o i ly  as growth factor receptors but also to regulate the signal 
p tthways of invasion associated with MMP-9 in human pan- 
c~ eatic cancer. It is unclear how the CCK receptor antagonist 
ctn inhibit the invasiveness in these cell lines. Protein kinase C 
0 'KC)  is thought to be an important signal transducer of 
MMP-9 in rat embryo fibroblasts [24]. From this point of 
ew, we are investigating the relationship between the CCK 
r~ceptor and the signal pathways of MMP-9 mediated by 
PKC. 
In conclusion, our data suggest hat LXG may be a useful 
ttterapeutic agent against pancreatic ancer. Further studies 
x~ ill be needed to clarify the signal pathways of MMP-9, 
a ld to evaluate LXG as a useful therapeutic agent against 
t+~e invasion of pancreatic ancer in vivo. 
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1-ig. 3. Western blot analysis. Culture media were collected and sub- 
jected to immunoblot analysis with a mouse monoclonal anti-MMP- 
9 antibody (IM 10). (A) PANC-1 treated with CCK-8. The concen- 
trations of CCK-8 were as follows: 0 (lane 1), 10 -9 (lane 2) and 
p)-s M (lane 3). (B) MIA PaCa-2 treated with CCK-8. The concen- 
trations of CCK-8 were as follows: 0 (lane 1), 10 -9 (lane 2) and 
1') -s M (lane 3). (C) PANC-1 treated with LXG. The concentra- 
t~3ns of LXG were as follows: 0 (lane 1), 1 (lane 2), 5 (lane 3), 10 
(lane 4), and 50 ~M (lane 5). (D) MIA PaCa-2 treated with LXG. 
"fhe concentrations of LXG were as follows: 0 (lane 1), 1 (lane 2), 
5 (lane 3), 10 (lane 4), and 50 ~tM (lane 5). The arrowhead indicates 
the position of MMP-9. 
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Fig. 4. Gelatin zymogram. The media were collected and subjected 
to zymography. (A) PANC-I treated with CCK-8. The concentra- 
tions of CCK-8 were as follows: 0 (lane 1), 10 -9 (lane 2) and 10 -s 
M (lane 3). (B) MIA PaCa-2 treated with CCK-8. The concentra- 
tions of CCK-8 were as follows: 0 (lane 1), 10 -9 (lane 2) and 10 -s 
M (lane 3). (C) PANC-1 treated with LXG. The concentrations of
LXG were as follows: 0 (lane 1), 1 (lane 2), 5 (lane 3), 10 (lane 4), 
and 50 pM (lane 5). (D) MIA PaCa-2 treated with LXG. The con- 
centrations of LXG were as follows: 0 (lane 1), 1 (lane 2), 5 (lane 
3), 10 (lane 4), and 50 ~tM (lane 5). The arrowhead indicates the 
position of MMP-9. 
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